New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus SurgeryGlobeNewsWire • 09/05/24
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 08/26/24
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQGlobeNewsWire • 05/17/24
Optinose Reports First Quarter 2024 Financial Results and Recent Operational HighlightsGlobeNewsWire • 05/14/24
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 05/02/24
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionGlobeNewsWire • 04/25/24
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsGlobeNewsWire • 03/15/24
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsGlobeNewsWire • 03/07/24
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In PracticeGlobeNewsWire • 01/18/24
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCEGlobeNewsWire • 12/06/23